At birth testicular androgens irreversibly program brain centers involved in hypothalamopituitary control of hepatic sex-dependent steroid and drug metabolism. This imprinting process results in activation of a hypothalamic "feminostatin"-a secreting center that is turned on just before puberty. Feminostatin inhibits pituitary secretion of "feminizing factor," a pituitary hormone that feminizes the basal type of metabolism characterizing the liver of hypophysectomized and gonadectomized rats. Consequently, female rats that are devoid of feminostatin will secrete feminizing factor from the pituitary, leading to a feminine type of hepatic metabolism. Male rats have an active feminostatin-secreting center, and inhibition of pituitary feminizing factor release results in an autonomous type of liver metabolism. Female rats show a relative androgen unresponsiveness and seem incapable of releasing feminostatin after treatment with natural androgens, possibly because of more efficient metabolism (breakdown) of androgen in the female than in the male rat brain.
Introduction
Primary liver cancer has been reported to be more frequent in men than in women (1) (2) (3) (4) and a greater male susceptibility to the induction of liver cancer by carcinogens such as N-2-fluorenylacetamide has also been found in several rat strains (5) (6) (7) . Removal of the testes decreased the tumor incidence in the experimental animals (8, 9) and substitution with androgen restored the responsiveness (8) . Long-term treatment with androgenic steroids has also been claimed to increase the risk for development of hepatocellular carcinoma in humans (10) . In rats, testosterone was reported to act indirectly via endocrine tissue(s) to increase chemical hepatocarcinogenesis (11) . Recently, Toh found that bilateral electrolytic lesions placed in the median eminence area of the hypothalamus in adult male rats had an inhibitory effect on liver tumor induction by N-2-fluorenylacetamide (12) . This experiment indicated a role of the hypothalamus in determining the susceptibility of the liver to toxic agents.
Since several years we have been involved in studies on mechanisms involved in regulation of sex differences in hepatic metabolism of steroids and drugs (13) . Based on our findings, we have suggested the existence of a novel endocrine control system, the hypothalamo-pituitary-liver axis, of major importance in regulation of hepatic metabolism. It is apparent to us that the results on liver toxicity described above may well be understood in view of this new concept of control of liver function and therefore the present paper will review some aspects of hypothalamo-pituitary regulation of hepatic metabolism.
Central Control of Hepatic Steroid and Drug Metabolism
In the early 1950's, Hubener and Amelung (14) showed a sex-related difference of hepatic cortico-130 steroid metabolism in the rat. This finding was substantially confirmed by subsequent reports using corticosteroids (15) (16) (17) , androgens (16) (17) (18) , and estrogens (18) as substrates. Male animals show a higher hydroxylating activity than females (17, 18) , whereas females exhibit a higher 5oa-reductase activity (16) . Somewhat later, Yates et al. (16) published the first study indicating that androgens were involved in the control of steroid metabolism in rat liver. It was found that castration increased and testosterone treatment decreased the 5a-reductase activity. This finding was confirmed and extended by , who showed the dependence of the adult male pattern of metabolism on the presence of neonatal androgen (imprinting). Although dependent on neonatal androgen exposure, no sex-related differences in steroid metabolism were observed until 30 days of age (23) (24) (25) (26) (27) . Sex-related differences in metabolism and the androgen-dependence of these differences have also been observed for the metabolism of various drugs and xenobiotics including ethylmorphine (28) , aniline (29) , p-nitroanisole (30) , and hexobarbitone (31) . The absence of any sex-specific androgen receptor in the liver (32) coupled to the fact that male animals are more sensitive to androgen action as regards hepatic steroid metabolism in the adult period (22, 33) seems to indicate an indirect action of androgen on hepatic steroid metabolism.
A possible explanation of the indirect action of androgens on hepatic steroid metabolism was put forward in 1974, when Denef (34) and Gustafsson and Stenberg (35) published the effects of hypophysectomy on hepatic steroid metabolism. Both groups showed that hypophysectomy of female animals resulted in a male pattern of metabolism, indicating that the female pattern of metabolism is dependent on the presence of an intact pituitary. It is well known that the hypothalamus in the rat is sex-differentiated with regard to control of pituitary secretion (36) and thus it is likely that the Environmental Health Perspectives sex-related difference in hepatic steroid metabolism observed is secondary to the sexual differentiation of the brain at birth and that androgens have their action via the hypothalamo-pituitary axis rather than directly on the liver. The pituitary dependence of hepatic metabolism is not confined to steroid metabolism although both androgen (34, 35) and corticosteroid (37) (34, 43) . We also showed that different time periods were required for the changes in different enzyme activities (44) , emphasizing the importance of the sensitivity of the respective enzyme system to the controlling factor(s). This would seem to indicate that the ectopic pituitary gland secretes a factor into the general circulation that is normally only secreted by the female pituitary gland in situ. The ectopic pituitary tissue is known to secrete prolactin and growth hormone and small amounts of the other anterior pituitary hormones (45) (46) (47) (48) . In our experiments only prolactin and growth hormone could be measured in the serum of implanted animals (44 Gustafsson and Stenberg (49, 50) have shown an effect of FSH but no effect of LH or prolactin on hepatic steroid metabolism when 4-androstene-3,17-dione is used as substrate. These results are in agreement with those of Colby et al. (37) , where corticosterone was used as substrate, and gain further confirmation from the April 1981 study of Lax et al. (45) , where the effect of prolactin on reductive metabolism was examined. In the report of Colby et al. (37) , a combination of GH and ACTH decreased reductive metabolism (an effect similar to hypophysectomy), while Lax et al. (51) found that prolactin had this effect. A later report by Kramer and Colby (52) indicated that GH alone increased reductive metabolism of steroids (an effect dramatically opposite to that of GH combined with ACTH). In the field of drug metabolism, ACTH and GH seem to be the most active. GH alone was thought to reduce the hepatic metabolism of ethylmorphine (52, 53) and aminopyrine (53) , whereas combinations of ACTH and GH have been shown to increase the carcinogenicity of N-hydroxy-N-2-fluorenylacetamide (54, 55) (thereby indicating a decrease in dehydroxylation and deacetylation ofthe carcinogen by the liver). Kramer et al. (56) have reported that both LH and FSH, when given to castrated male and female rats, increased ethylmorphine demethylase activity in the liver.
None of the above mentioned effects are, however, as marked as that seen after implantation of a pituitary gland under the kidney capsule. These data would indicate that the control of hepatic steroid and xenobiotic metabolism is mediated via an, as yet, unidentified pituitary factor (or possibly an unidentified combination of factors)-we have labelled this factor "feminizing factor" or "feminotropin." The purification of this factor is underway in our laboratory.
Studies by our group (57, 58) on the ontogenesis of the pituitary control of hepatic steroid metabolism have indicated that the liver and pituitary are not per se sex differentiated with regard to their response to and production of "feminizing factor," respectively. Thus, the masculinized ("imprinted") control center must lie elsewhere.
The possibility that hepatic steroid metabolism is under indirect hypothalamic control was first indicated by our above-mentioned finding (59) that complete electrothermal destruction of the hypothalamus in male rats resulted in "feminization" of the steroid metabolism in the liver of the operated animals. This indicated for the first time that, in the male rat, release of the factor(s) maintaining a female-type steroid metabolism in female animals was inhibited by the hypothalamus. This inhibitory control is similar to that of prolactin, the release of which is inhibited by prolactin release inhibiting factor (PIF) (60) .
The site of the sexual differentiation in the hypothalamus appears to lie predominantly in the preoptic area where, in fact, anatomical differences in nerve structure can be found. Greenough et al. (62) (63) (64) (65) . In order to ascertain more exactly the area of the hypothalamus that controls the secretion of feminizing factor, a series of experiments was performed by our group (66) whereby the effects of various brain lesions on hepatic steroid metabolism were investigated. Two distinct types of lesions were perforned: one, anterior hypothalimic deafferentation and two, discrete lesions in the rostral parts of the hypothalamus. One week after the lesioning, the animals were killed and their hepatic steroid metabolism investigated. The effects of the lesions on steroid metabolism were correlated to the changes in secretion of pituitary hormones.
Hypothalamic deafferentation about the level of A5660,u [according to the atlas of Jacobovitz and Palkovits (94)] (posterior to the preoptic area and thus separating the rostral parts of the hypothalamus from the medial basal hypothalamus including the median eminence) ( Fig. 1) caused complete "feminization" of hepatic steroid metabolism in the operated male animals while having little effect on the female animals (66). These results indicate that the center of control lies anterior to the level of A5660,u, possibly in the suprachiasmatic nucleus or in the surrounding periventricular area. This finding is in contrast to the proposed regulatory site for prolactin secretion which lies within the boundaries 132 of the deafferentation. In order to further investigate the possible involvement of the hypothalamic areas, a number of discrete lesions were placed in various positions in this area and their effects on hepatic steroid metabolism studied. A comparatively large midline lesion placed in the periventricular region and stretching between levels A719O0, and A566O1j. (i.e., roughly located anterior to the level of the deafferentation) caused complete feminization of steroid metabolism in the livers of operated male animals while having only small effects on female animals. However, lesions in the midline but occupying only the more rostral aspects of the lesion mentioned above (stretching from levels A789O0, to A6670,u) were without effect indicating that the essential areas involved in the control of the secretion of feminizing factor lie caudally to the level A667O0,; i.e., approximately extending from the beginning of the suprachiasmatic nucleus in a caudal direction.
Bilateral lesions essentially involving the nuclei interstitialis striae terminalis but also extending medially including the anterior commissure caused a moderate degree of feminization indicating that higher centers may be involved in the regulation of the secretion of feminizing factor. Small bilateral lesions in the lateral preoptic area were without effect on steroid metabolism in the livers of the lesioned rats. The question may now be asked whether the effects of androgens and estrogens on the liver may be mediated via the hypothalamus. Much work has been done on the presence of receptors for sex steroids in the brain particular as regards the hypothalamus. We have shown the existence of specific androgen receptors in several brain regions including the hypothalamus, cortex and pituitary gland (67) . In the same study we found that there appears to be a sexual dimorphism of androgen metabolism in rat brain (67) . Testosterone was metabolized predominantly to androstenedione in the male but to 5a-androstane-3a(or 3,B), 17p-diol, epitestosterone and dihydroepitestosterone in the female. The metabolism of testosterone was also much faster in female than male brains. This could explain the relative androgen unresponsiveness in the female.
With regard to the actions of estrogens, it is well accepted that specific estrogen receptors exist in the hypothalamus and that binding of estrogen to these receptors can cause biochemical and physiological changes in the receptor-containing brain areas. We have recently developed a highly sensitive and specific method for estradiol receptor quantitation, based on isoelectric focusing in polyacrylamide gel, and we have used this method Environmental Health Perspectives to study sexual differences in distribution of estradiol receptors in the brain (68) . The highest concentrations of estradiol receptor were found in amygdala and anterior and posterior hypothalamus. All of these data would seem to indicate that the hypothalamus (and pituitary gland) is capable of reacting to estrogens (in both sexes) and androgen (only in the male). It is thus likely that most, if not all, effects of sex steroids on hepatic steroid metabolism are indirect and mediated via the hypothalamo-pituitary system. Furthermore, it is the hypothalamus that is imprinted at birth by androgens exactly as has been demonstrated for the adult patterns of sexual behavior and release of gonadotropins.
Our proposed theory for the imprinting of hepatic steroid metabolism in the rat is shown in Figure 2 . Imprinting occurs entirely in the hypothalamus where androgen in the neonatal period alters the anatomical, physiological and biochemical workings. This area, which we have labeled the "feminostatin" center, since we think it produces the feminizing factor release-inhibiting factor, is only active in the male. Androgen in the neonatal period is essential for activation of the center. In the normal adult male, the activated feminostatin center produces and releases feminostatin which, in turn, inhibits the release of feminizing factor from the pituitary gland. This leads to a masculine pattern of hepatic metabolism. In the female, the feminostatin center is inactive, and thus feminizing factor is released from the pituitary gland giving a feminine pattern of hepatic metabolism. Androgens are active in the male in the adult period by interaction with the androgen receptors in the brain while estrogens are active in both sexes via the estrogen receptors in the hypothalamus and pituitary gland. It is probable that the effects of the sex steroids are mediated via the feminostatin center, but a direct effect on the pituitary gland cannot be ruled out.
Central Control of Prolactin (PrI) Receptors in the Liver
During recent years, we have studied another sex-differentiated liver function quite extensively, namely the concentration of prolactin receptors. It has become more and more evident that also this system is controlled by the hypothalamo-pituitary axis and that, indeed, the feminizing factor or a similar factor may be responsible for the maintenance of prolactin receptors in the female rat liver. Some of our recent findings on regulation of hepatic prolactin receptors will be presented below.
In 1974, Friesen's group showed the existence of a receptor in rat liver that bound both ovine prolactin and human growth hormone (69, 70) . It was found that this receptor was present in much higher concentrations in female than male rats. These findings have been confirmed by other groups including our own (71) (72) (73) (74) . The development of these receptors has been shown to follow that of the steroid-metabolizing enzymes rather closely. No sex differences were found in lactogenic receptor concentration in prepubertal rats, but between 20 and 40 days of age a marked increase in the receptor level in female rats occurred (there was no concomitant change in the male) (70) . This should be compared to the development of, for example, the 5a-reductase (active on 4-androstene-3,17-dione) (27) ; this enzyme was found in low concentrations in prepubertal rats but developed rapidly in females around 30 days of age leading to the marked sex differences in activity noted in the adult period.
The level of "lactogenic" receptors in rat liver seemed to depend upon the level of androgen and estrogen. Ovariectomy reduced and castration increased the number of "lactogen" binding sites whereas replacement therapy with the appropriate steroid reversed the effect of the glandular ablation (72, 75, 76) . Male animals injected with estrogens showed a marked increase in "lactogenic" binding while females treated with testosterone displayed lower binding than controls. This again is a very similar situation to that found for the enzymes 133 (76) . It is interesting to note that both of these tumors have also been shown to feminize the rat liver with regard to steroid metabolism (80) .
The hypothesis put forward that prolactin regulates the lactogenic receptors in rat liver no longer seems to hold true following the work of Posner (76) , who showed that replacement therapy with pure ovine prolactin was without effect in hypophysectomized animals. Recently, treatment of hypophysectomized females bearing a pituitary graft with the dopaminergic agonist, CB-154 (discussed above), has been shown to be ineffective in eliminating the lactogenic receptor-inducing capacity of the implant although serum prolactin levels drop below the detectable limit (75) .
In our own work (74-81), the prolactin-induced lactogenic receptor concept has been consistently challenged. We have also found no effect of CB-154 on hepatic receptor level either in normal or pituitary-transplanted animals. In addition, extensive work involving hypothalamic deafferentation has indicated no correlation between effect on serum prolactin level and "lactogenic" receptor level (see below).
Even the physiological ligand for the "lactogenic" receptor in rat liver is still in question. Friesen and his group have assumed that binding of ovine prolactin to rat liver is a measure of the binding of rat prolactin to the same receptor. This does not necessarily have to be the case, however, as indicated by the work of Posner (76) where both ovine prolactin and human growth hormone were shown to be about five times as effective as rat prolactin in displacing bound labelled ovine prolactin. Rat growth hormone did not displace ovine prolactin at all from the lactogenic receptor.
Ranke et al. (82, 83) , working with isolated hepatocytes, have shown that in this system rat prolactin was also 10 times less effective than ovine prolactin as a displacer and that rat growth hormone was also ineffective as a displacing agent. Other groups working with isolated cell systems have shown binding of ovine prolactin and human growth hormone (84, 85) Experiments were also performed to study the effect of hypothalamic lesions on hepatic hPrl receptors. The effect of anterior hypothalamic deafferentation on hPrl receptors in liver was studied as a function of the length of the interval between operation and decapitation (Fig. 3) the female level. The induction of hPrl receptors was evident 3 days following the operation with a maximum after 4 days (Fig. 3) . The rise in the concentration of hPrl receptors in the liver was not accompanied by an increase in serum Prl (Fig. 3) . Scatchard analysis showed that the induced receptors in the lesioned male rats had similar ligand affinity as the receptors in control female rats (KD values 0.6 and 0.5 x 10-9M, respectively). Similar binding capacities were also seen in lesioned males and control females (81 and 102 fmole/mg, respectively). In order to further localize the "receptor-regulating" center(s) in the brain, transections were performed at a more anterior level. The induction of hepatic hPrl receptors following a lesion at the retrochiasmatic level was not seen in animals with the more anterior transection.
The results presented indicate that hypothalamic 135 SPEC. BOUND (1.) (4) deafferentation at the retrochiasmatic level severs the connection between an inhibitory center in the brain which under normal conditions depresses pituitary secretion of a receptor-inducing factor in the male. The exact localization of this brain center remains to be determined. However, since no effect was seen when transections were placed rostral to the suprachiasmatic nucleus, this suggests that the suprachiasmatic and preoptic area may be essential for the control of induction of hPrl receptors. It remains to be elucidated whether a "center" is located in the area between the two levels of transections or whether this area is traversed by passing fiber systems coming in from the lateral aspects to turn caudally towards the basal hypothalamus.
The nature of the hypophyseal receptor-inducing factor is uncertain. Retrochiasmatic deafferentation 136 is likely to interfere with the LH-RH system; destruction of the suprachiasmatic nucleus has been reported to inhibit the phasic component of the LH release (89) . In view of the finding that castration increases the Prl receptors (90) , part of the hepatic hPrl receptor induction following deafferentation could possibly be a castration-like effect. However, it is not likely that the large increase of hPrl receptors after deafferentation could solely be a castration-like effect, since castration alone does not increase the Prl receptors to a female level (91) . The finding that high liver hPrl receptor levels were not accompanied by high serum Prl levels (Fig. 3) , does not agree with earlier suggestions that Prl could be the inducing agent of its own receptor.
Using Alzet osmotic minipumps (Alza corporation, Palo Alto, Cal) (92) (75, 90) . A group of untreated female rats was included in all of the following experiments. As shown in Figure 4 , hGH induced a "feminine" Prl receptor level in livers of hypophysectomized and castrated animals of both sexes.
To ascertain that the effect of hGH was not mediated via the adrenals or thyroids, these organs were removed in male rats. induce a "feminine" hepatic Prl receptor level was unchanged in thyroidectomized-adrenalectomized rats (Fig. 5 ) when compared to hypophysectomizedgonadectomized animals. The Prl-receptor-inducing effect of hGH, which apparently did not require the presence of pituitary, thyroid, adrenals or gonads, was then investigated in intact male rats with regard to its time course (Fig. 6 ). An increase of the receptor concentration to a female level was observed after 4-7 days of hGH administration.
The induced Prl receptors had similar characteristics as the receptors present in control females when calculating data according to Scatchard Figure 7 shows the effect of varying concentrations of hGH in minipumps on receptor levels in male rats. Induction to female Prl receptor levels was seen with 2.5 pug/pi and 5 ,ug/,l (or 5 mU/,ul and 10 mU/,ul, respectively).
The effects of rat hornone preparations were then investigated. Rat GH and rat Prl were administered to hypophysectomized male rats in osmotic minipumps (10 ,ug/,l in hypophysectomized-gonadectomized rats given hGH: 111 4% (from experiment shown in Fig.  4a ). Hypophysectomized control rats or animals given rPrl showed no weight increase. Administration of rGH to hypophysectomized rats increased serum levels of GH from 22 ± 5 ng/ml to 64 ± 22 ng/ml. Administration of rPrl resulted in serum Prl levels of 28 ± 17 ng/ml as compared to the levels in hypophysectomized controls which were less than 2.5 ng/ml. Administration of rPrl did not affect hepatic Prl receptor levels in hypophysectomized male rats (Fig. 8) Prl-receptor-inducing activity of hGH was not dependent on the presence of the pituitary, thyroid, adrenals or gonads. The induction time was between 4 and 7 days. Other workers have failed to see an effect of hGH on hepatic Prl receptor levels, although it was administered three times a day in higher doses than that used in the present investigation (79) . This may indicate that a continuous hormone administration is necessary for induction. Since, to our knowledge, it has not proved possible to study hepatic Prl receptor induction in an in vitro system, osmotic minipumps would seem to be advantageous to use in investigations on induction of Prl receptors. The effect of hGH indicates that either a lactogenic or a somatogenic or a combined principle is responsible for Prl receptor induction. Any definite conclusion as to the nature of the endogenous hormone causing receptor induction cannot be drawn. Due to the small quantities of rPrl and rGH available, we could only test these hormones at one concentration. At this concentration, rPrl was not effective in inducing hepatic Prl receptors. Also previous experiments, where hypothalamic lesions in male rats were found to lead to induction of hepatic Prl receptors without a concomitant increase in serum Prl (13, 81) the liver. The same concentration of rGH as was found to be without effect in case of rPrlt resulted in an increased hepatic Prl receptor level, although not as high as in female rats. This would favor the idea that the inducing hormone is GH or a GH-like peptide. Further studies are required with more purified preparations of rPrl and rGH as well as with combinations of these hormones in order to clarify this matter. Another possibility is that a contaminant of the NIAMDD rGH B6 preparation is the responsible hormone. In this context, it is interesting to once more draw the attention to the regulation of the sex differences in steroid and drug metabolism in rat liver (43) . Also here we have proposed a novel pituitary factor acting on the liver (93) . Considering the many similarities between control of steroid metabolism and Prl receptors, the same pituitary factor might be involved in both cases.
General Comments
The hypothalamo-pituitary-liver axis represents a new concept in endocrine regulation of drug toxicity. The male rat liver has been shown to be more susceptible than the female rat liver to the hepatocarcinogenic action of certain drugs and it is conceivable that sex differences in the metabolic activation of the drugs in the liver may explain the greater sensitivity of male rats to chemically induced hepatocellular carcinoma. Similar sex differences in liver cancer incidence have been reported in the human. Further studies on pituitary-regulated metabolic activation of chemical carcinogens in the liver may lead to a deeper understanding of control of chemical carcinogenesis also in other tissues regulated by pituitary hormones, e.g., the breast and the prostate.
